Lausanne, Switzerland, July 10, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates on the advancement of its in-house and partnered product candidates and technology platforms will be provided at the Alzheimer's Association International Conference (AAIC 2017 © ). The conference is the largest international meeting dedicated to advancing dementia science and takes place in London, UK from July 15 th to July 20 th , 2017.
| Program and Collaborator | Presentations and Timing |
| Crenezumab / Genentech | Mathematical model of amyloid beta dynamics to assess target engagement of soluble amyloid beta oligomers by crenezumab in the Alzheimer's disease brain Poster - July 16 / 9:30 - 16:15 (S8, P109) Safety and tolerability of crenezumab in mild-to-moderate AD patients treated with escalating doses for up to 25 months Oral presentation - July 17 / 17:30 - 17:45 (N10 ) |
| anti-Tau antibody / Genentech | Changes in Tau protein landscape during Alzheimer's disease progression Poster - July 19 / 9:30 - 16:15 (S8) A Phase 1 Study to evaluate the safety and tolerability of RO7105705 in healthy volunteers and patients with mild-to-moderate AD Oral Presentation - July 17 / 16:45 - 17:00 (N10, P99) |
| Tau-PET imaging agent / Piramal | First in human PET studies with the next generation Tau agent 18F-PI-2620 in Alzheimer's disease, progressive supranuclear palsy and controls Oral Presentation - July 15 / 10:00 - 10:15 (S10-C) Preclinical characterization of PI-2620, a novel Tau-PET-tracer for detection of Tau in AD and other Tauopathies Poster - July 15 / 12:15 - 13:30 (S9, P192) Preclinical Characterization of PI-2620, a Novel Tau PET Tracer for detection of Tau in AD and other Tauopathies Poster - July 17 / 9:30- 16:15 (S8, P381) |
| AC Immune vaccine technology | Development of highly sensitive MSD assays for the detection of anti-amyloid beta monomer and oligomer-specific antibodies in human serum Poster - July 18 / 9:30-16:15 (S8, P67) |
About AC Immune AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer's disease. The Company's pipeline features seven therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Abeta antibody in phase 3 clinical studies that is being advanced by the collaboration partner Genentech, Inc., a wholly owned subsidiary of Roche. Other business partners include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Essex Bio-Technology.
Forward looking statements This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information-Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
For further information please contact:
| Prof. Andrea Pfeifer Chief Executive Officer Phone: +41 21 345 91 21 E-mail: andrea.pfeifer@acimmune.com | Eva Schier Corporate Communications Manager Phone: +41 21 345 91 34 Mobile: +41 79 926 66 03 E-mail: eva.schier@acimmune.com |
| Nick Miles/Toomas Kull Cabinet Privé de Conseils s.a. Phone: +41 22 552 46 46 E-mail: miles@cpc-pr.com kull@cpc-pr.com | In the US Ted Agne The Communications Strategy Group Inc. Phone: +1 781 631 3117 E-mail: edagne@comstratgroup.com |
Attachments:
